Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials

摘要: Randomized controlled trials (RCTs) showed inconsistent results regarding the efficacy of angiotensin II receptor blockers (ARBs) on portal pressure as indicated by hepatic venous gradient (HVPG). A meta-analysis RCTs was performed to evaluate influence ARBs treatment HVPG. PubMed, Embase, and Cochrane’s Library were searched for relevant RCTs. fixed or a randomized effect model used pool according heterogeneity. Subgroup analyses explore source Eleven with 394 patients included. did not significantly change HVPG compared controls (weighted mean difference [WMD] = −0.63, 95% confidence interval [CI] −1.73 0.47 mmHg, p = 0.26; I2 = 60%). These consistent in studies comparing propranolol (WMD = −0.40, CI −2.22 1.41 mmHg, p = 0.67; I2 = 68%), those non-active including placebo no (WMD = −1.05, −2.33 0.24 mmHg, p = 0.13; I2 = 44%). also affected individual used. Moreover, reduced arterial blood (WMD = −6.12, −9.69 −2.55 mmHg, p = 0.008; I2 = 53%), risk symptomatic hypotension increased (RR = 4.13, 0.94 18.18, p = 0.06; I2 = 0%). reduce cirrhosis; moreover, may increase.